Login / Signup

Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.

Zhanfang GuoJingqin R LuoR Jay MashlJeremy HoogPiyush MaitiNicole FettigSherri R DaviesRebecca AftJason M HeldRamaswamy GovindanLi DingShunqiang LiCornelius von MorzeGerburg M WulfKooresh I ShoghiCynthia X Ma
Published in: Cancer research communications (2024)
In this research, we demonstrated that the pan-PI3K inhibitor copanlisib enhanced the cytotoxicity of eribulin in a panel of TNBC PDX models. The improved tumor growth inhibition was irrespective of PI3K pathway alteration and was corroborated by the enhanced mitotic arrest and apoptotic induction observed in PDX tumors after combination therapy compared with each drug alone. These data provide the preclinical rationale for the clinical testing in TNBC.
Keyphrases